Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular hypertrophy in renal failure

K Amann1, I Rychlík, G Miltenberger-Milteny

  • 1Department Pathology and Internal Medicine, University of Heidelberg, Germany.

Kidney International. Supplement
|December 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.

Clinical nephrology·1992
Same author

Reduced capillary density in the myocardium of uremic rats--a stereological study.

Kidney international·1992
Same author

Renal histology in polycystic kidney disease with incipient and advanced renal failure.

Kidney international·1992
Same author

The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease.

Journal of the American Society of Nephrology : JASN·1992
Same author

Severe hemorrhagic complications from infection with nephropathia epidemica strain of Hantavirus.

Clinical nephrology·1992
Same author

Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.

Kidney international. Supplement·1992

Left ventricular hypertrophy (LVH) affects most patients with kidney failure, increasing cardiac death risk. Managing fluid overload, anemia, and blood pressure is key to reducing LVH in these patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Left ventricular hypertrophy (LVH) is highly prevalent in end-stage renal disease (ESRD) patients, affecting 60-80% initiating renal replacement therapy.
  • Multiple factors contribute to LVH in ESRD, including fluid overload (hypervolemia), increased vascular resistance (afterload), anemia, arteriovenous fistulas, arterial stiffness, and local neurohormonal activation (renin-angiotensin-aldosterone system, endothelin).

Purpose of the Study:

  • To summarize the pathophysiology and clinical significance of LVH in patients with kidney failure.
  • To highlight the predictive value of LVH for cardiac mortality in dialyzed patients.
  • To discuss current strategies for LVH reduction in this population.

Main Methods:

  • Review of existing literature on LVH in renal failure patients.

Related Experiment Videos

  • Analysis of factors contributing to LVH, including hemodynamic and local system influences.
  • Examination of the prognostic implications of LVH and potential therapeutic interventions.

    • Main Results:

    • LVH is a common complication of terminal renal failure, presenting as mixed eccentric and concentric patterns.
    • LVH independently predicts cardiac death in dialyzed patients, irrespective of blood pressure.
    • Renal patients with LVH exhibit distinct microvascular disease and interstitial fibrosis compared to non-renal hypertensive individuals.
    • LV remodeling can initiate early, even in normotensive patients with glomerulonephritis and normal glomerular filtration rate (GFR).

    Conclusions:

    • LVH is a critical determinant of cardiac outcomes in patients with kidney failure.
    • Therapeutic strategies should focus on managing hypervolemia, optimizing hemoglobin levels, controlling blood pressure (especially with ACE inhibitors), and addressing contributing factors.
    • Early detection and intervention for LV remodeling are crucial, even in early stages of kidney disease.